Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2004 1
2005 2
2006 4
2007 3
2008 12
2009 13
2010 18
2011 17
2012 21
2013 21
2014 27
2015 41
2016 41
2017 35
2018 48
2019 54
2020 50
2021 80
2022 76
2023 73
2024 63
2025 76
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

690 results

Results by year

Filters applied: . Clear all
Page 1
Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders.
Ringelstein M, Ayzenberg I, Lindenblatt G, Fischer K, Gahlen A, Novi G, Hayward-Könnecke H, Schippling S, Rommer PS, Kornek B, Zrzavy T, Biotti D, Ciron J, Audoin B, Berthele A, Giglhuber K, Zephir H, Kümpfel T, Berger R, Röther J, Häußler V, Stellmann JP, Whittam D, Jacob A, Kraemer M, Gueguen A, Deschamps R, Bayas A, Hümmert MW, Trebst C, Haarmann A, Jarius S, Wildemann B, Grothe M, Siebert N, Ruprecht K, Paul F, Collongues N, Marignier R, Levy M, Karenfort M, Deppe M, Albrecht P, Hellwig K, Gold R, Hartung HP, Meuth SG, Kleiter I, Aktas O; Neuromyelitis Optica Study Group (NEMOS). Ringelstein M, et al. Among authors: meuth sg. Neurol Neuroimmunol Neuroinflamm. 2021 Nov 16;9(1):e1100. doi: 10.1212/NXI.0000000000001100. Print 2022 Jan. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34785575 Free PMC article.
[Neuroimmunology without limits].
Meuth SG. Meuth SG. Nervenarzt. 2024 Oct;95(10):889-893. doi: 10.1007/s00115-024-01700-x. Epub 2024 Sep 26. Nervenarzt. 2024. PMID: 39325102 Free PMC article. German. No abstract available.
Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis: Results From the Randomized Phase 2 Vivacity-MG Study.
Antozzi C, Guptill J, Bril V, Gamez J, Meuth SG, Nowak RJ, Quan D, Sevilla T, Jouvin MH, Jin J, Karcher K, Ramchandren S, Sun H, Ling L, Zhu Y, Arroyo S; Vivacity-MG Phase 2 Study Group. Antozzi C, et al. Among authors: meuth sg. Neurology. 2024 Jan 23;102(2):e207937. doi: 10.1212/WNL.0000000000207937. Epub 2023 Dec 21. Neurology. 2024. PMID: 38165333 Free PMC article. Clinical Trial.
Primary Angiitis of the CNS: A Systematic Review and Meta-analysis.
Beuker C, Strunk D, Rawal R, Schmidt-Pogoda A, Werring N, Milles L, Ruck T, Wiendl H, Meuth S, Minnerup H, Minnerup J. Beuker C, et al. Among authors: meuth s. Neurol Neuroimmunol Neuroinflamm. 2021 Oct 18;8(6):e1093. doi: 10.1212/NXI.0000000000001093. Print 2021 Nov. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34663675 Free PMC article.
Immunology of multiple sclerosis: an update.
Kirschner P, Pawlitzki M, Hartung HP, Meuth SG. Kirschner P, et al. Among authors: meuth sg. Curr Opin Neurol. 2025 Jun 1;38(3):180-187. doi: 10.1097/WCO.0000000000001361. Epub 2025 Apr 30. Curr Opin Neurol. 2025. PMID: 40326581 Review.
Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders.
Konen FF, Möhn N, Witte T, Schefzyk M, Wiestler M, Lovric S, Hufendiek K, Schwenkenbecher P, Sühs KW, Friese MA, Klotz L, Pul R, Pawlitzki M, Hagin D, Kleinschnitz C, Meuth SG, Skripuletz T. Konen FF, et al. Among authors: meuth sg. Autoimmun Rev. 2023 May;22(5):103312. doi: 10.1016/j.autrev.2023.103312. Epub 2023 Mar 15. Autoimmun Rev. 2023. PMID: 36924922 Free article. Review.
Multiple sclerosis endophenotypes identified by high-dimensional blood signatures are associated with distinct disease trajectories.
Gross CC, Schulte-Mecklenbeck A, Steinberg OV, Wirth T, Lauks S, Bittner S, Schindler P, Baranzini SE, Groppa S, Bellmann-Strobl J, Bünger N, Chien C, Dawin E, Eveslage M, Fleischer V, Gonzalez-Escamilla G, Gisevius B, Haas J, Kerschensteiner M, Kirstein L, Korsukewitz C, Lohmann L, Lünemann JD, Luessi F, Meyer Zu Hörste G, Motte J, Ruck T, Ruprecht K, Schwab N, Steffen F, Meuth SG, Paul F, Wildemann B, Kümpfel T, Gold R, Hahn T, Zipp F, Klotz L, Wiendl H; German Competence Network Multiple Sclerosis (KKNMS). Gross CC, et al. Among authors: meuth sg. Sci Transl Med. 2024 Mar 27;16(740):eade8560. doi: 10.1126/scitranslmed.ade8560. Epub 2024 Mar 27. Sci Transl Med. 2024. PMID: 38536936
C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis.
Huntemann N, Gerischer L, Herdick M, Nelke C, Stascheit F, Hoffmann S, Öztürk M, Schroeter CB, Lehnerer S, Stein M, Schubert C, Schneider-Gold C, Pfeuffer S, Krämer HH, Konen FF, Skripuletz T, Pawlitzki M, Glaubitz S, Zschüntzsch J, Scherwietes V, Totzeck A, Hagenacker T, Meuth SG, Meisel A, Ruck T. Huntemann N, et al. Among authors: meuth sg. J Neurol Neurosurg Psychiatry. 2025 Mar 24;96(4):310-321. doi: 10.1136/jnnp-2024-334404. J Neurol Neurosurg Psychiatry. 2025. PMID: 39798960 Free PMC article.
690 results